In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition.
The study, conducted by a team at Beth Israel Medical Center and Harvard University analyzed blood samples taken from 140 individuals who never suffered from Covid, those who got infected and fully recovered, and those who got the infection and developed long Covid.
The research team used a multi-omic approach to analyze those blood samples. This involved testing for viral markers, plasma proteins, gene expression, immune responses and other advanced tests. These tests allowed the researchers to understand the inflammatory and immune system responses of the individuals studied. The analysis covered the initial three months after one has been infected with Covid and then up to half a year after the infection.
The results uncovered distinct differences in certain signaling pathways that could help in explaining why some people ended up with long Covid while others didn’t develop this chronic condition.
The scientists found that the people who had high levels of inflammation markers in their immune system stood the highest chance of developing long Covid after they were infected by the SARS-CoV-2 virus. The research identified important signaling pathways that merit further study as targets for teams developing treatments to address long Covid.
This study is important because initial attempts to treat long Covid focused on administering therapeutics aimed at dealing with lingering viral particles in the body. However, this approach hasn’t yielded significant results, suggesting that the problem may lie elsewhere. Looking into addressing immune system depletion and inflammatory pathways could offer better results since this new study highlights the role that these mechanisms play in triggering the different long Covid symptoms, such as brain fog, chronic fatigue, cognitive decline and intolerance to exercise, among others.
The research is yet another reminder of the long term effects of chronic inflammation in the body. For companies like Soligenix Inc. (NASDAQ: SNGX) that are investing resources in developing therapies indicated for chronic inflammation, this new understanding opens potential indications for which their drugs under development could be put to use once commercialized.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has…
A new study done in India has produced results that bring into question the longstanding assumption that…
Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”)…
A study that involved an analysis of patient records in New York has discovered that…
After the pandemic, public trust in the U.S. healthcare system plummeted, and officials at the…
Since 1991, there has existed a recommendation requiring all newborns to receive a vaccine against…